KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Travere Therapeutics (TVTX) Loans and Notes Receivables (2016 - 2017)

Travere Therapeutics' Loans and Notes Receivables history spans 3 years, with the latest figure at $47.2 million for Q1 2017.

  • For Q1 2017, Loans and Notes Receivables changed 0.0% year-over-year to $47.2 million; the TTM value through Mar 2017 reached $47.2 million, changed 0.0%, while the annual FY2016 figure was $46.8 million, 0.0% changed from the prior year.
  • Loans and Notes Receivables reached $47.2 million in Q1 2017 per TVTX's latest filing, up from $46.8 million in the prior quarter.
  • In the past five years, Loans and Notes Receivables ranged from a high of $47.5 million in Q2 2016 to a low of $46.5 million in Q3 2015.
  • Average Loans and Notes Receivables over 3 years is $46.9 million, with a median of $46.8 million recorded in 2015.
  • The largest YoY upside for Loans and Notes Receivables was 0.0% in 2016 against a maximum downside of 0.0% in 2016.
  • A 3-year view of Loans and Notes Receivables shows it stood at $46.8 million in 2015, then changed by 0.0% to $46.8 million in 2016, then rose by 0.69% to $47.2 million in 2017.
  • Per Business Quant, the three most recent readings for TVTX's Loans and Notes Receivables are $47.2 million (Q1 2017), $46.8 million (Q4 2016), and $46.5 million (Q3 2016).